Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizergan Offers Warm Embrace For Pfizer’s Internal And Allergan’s External R&D

Executive Summary

Pfizer R&D chief Mikael Dolsten and his counterpart at Allergan, David Nicholson, oversee very different research organizations, but in interviews at the J.P. Morgan Healthcare Conference the two heads of R&D insisted the chasm between their research models is not so vast.

You may also be interested in...



Q2 Earnings Round-Up Part 1: Signs Of Pandemic Recovery

Small-to-medium-sized companies launching their first or one of their only commercial products faced a particular difficult time during the pandemic. In the second quarter earnings calls, some of these SMEs are seeing momentum as the most serious COVID headwinds resolve but others are contending with ongoing challenges. [Check back tomorrow for Part 2 on companies experiencing continuing challenges.]

Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals

Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.

Lilly Is Revved Up About Alzheimer's Opportunity

The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS057387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel